Horizon Pharma launches $845.75 million repricing of term loan B

New York, Oct. 10 – Horizon Pharma, Inc. and Horizon Pharma USA, Inc. launched a repricing of their $845.75 million senior secured term loan B due March 29, 2024 (Ba2/BB-) with a lender call on Tuesday.

The covenant-light loan is talked at Libor plus 325 basis points with a 1% Libor floor, offered at par, according to a market source.

Included is 101 soft call protection for six months.

Citigroup is the sole lead arranger and administrative agent.

Horizon Pharma is a Dublin-based biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.